← Back to Search

Alkylating agents

Ca2+/Mg2+pre & post cycle 2 for Colorectal Cancer

Phase 1
Waitlist Available
Research Sponsored by AHS Cancer Control Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The investigators hypothesize that Ca2+/MG2+ infusions will not have a significant effect on oxaliplatin pharmacokinetics.

Eligible Conditions
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Ca2+/Mg2+pre & post cycle 2Active Control1 Intervention
Arm B:Ca2+/Mg2+: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 2
Group II: Ca2+/Mg2+ pre & post cycle 1Active Control1 Intervention
Arm A:Ca2+/Mg2+: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1

Find a Location

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
182 Previous Clinical Trials
26,816 Total Patients Enrolled
Michael Sawyer, MDStudy ChairAlberta Health services
13 Previous Clinical Trials
658 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top